Assays for prostate cancer: changing the screening paradigm?
Standard
Assays for prostate cancer: changing the screening paradigm? / Hansen, Jens; Rink, Michael; Graefen, Markus; Shariat, Shahrokh; Chun, Felix K-H.
In: MOL DIAGN THER, Vol. 17, No. 1, 01.02.2013, p. 1-8.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Assays for prostate cancer: changing the screening paradigm?
AU - Hansen, Jens
AU - Rink, Michael
AU - Graefen, Markus
AU - Shariat, Shahrokh
AU - Chun, Felix K-H
PY - 2013/2/1
Y1 - 2013/2/1
N2 - Prostate cancer (PCa) screening and detection have changed dramatically since the introduction of serum prostate-specific antigen (PSA) testing. Despite the resulting improvement in early PCa detection and stage migration, in clinical practice the use of PSA testing may cause overdetection and ultimately overtreatment. As a consequence, novel biomarkers are needed to increase the specificity of PCa detection. The aim of this article is to present an overview of novel blood- and urine-based biomarkers that may optimize PCa detection, with improved identification of patients with significant PCa and avoidance of unnecessary prostate biopsies. A systematic and comprehensive PubMed search was performed using the MeSH search terms 'prostate cancer', 'biomarker', 'marker', and 'detection'. Results were restricted to the English language. Several blood- and urine-based biomarkers have the potential to improve prediction of the presence and/or significance of PCa. Ideally, biomarkers should be used in combination within multivariate models, leading to superior accuracy for prediction of any PCa or clinically significant PCa, compared with the use of a single marker.
AB - Prostate cancer (PCa) screening and detection have changed dramatically since the introduction of serum prostate-specific antigen (PSA) testing. Despite the resulting improvement in early PCa detection and stage migration, in clinical practice the use of PSA testing may cause overdetection and ultimately overtreatment. As a consequence, novel biomarkers are needed to increase the specificity of PCa detection. The aim of this article is to present an overview of novel blood- and urine-based biomarkers that may optimize PCa detection, with improved identification of patients with significant PCa and avoidance of unnecessary prostate biopsies. A systematic and comprehensive PubMed search was performed using the MeSH search terms 'prostate cancer', 'biomarker', 'marker', and 'detection'. Results were restricted to the English language. Several blood- and urine-based biomarkers have the potential to improve prediction of the presence and/or significance of PCa. Ideally, biomarkers should be used in combination within multivariate models, leading to superior accuracy for prediction of any PCa or clinically significant PCa, compared with the use of a single marker.
KW - Annexin A3
KW - Antigens, Neoplasm
KW - Biopsy
KW - DNA
KW - Early Detection of Cancer
KW - Humans
KW - Male
KW - Plasminogen Activators
KW - Prostate-Specific Antigen
KW - Prostatic Neoplasms
KW - Sensitivity and Specificity
KW - Serine Endopeptidases
KW - Tumor Markers, Biological
U2 - 10.1007/s40291-013-0014-y
DO - 10.1007/s40291-013-0014-y
M3 - SCORING: Journal article
C2 - 23355098
VL - 17
SP - 1
EP - 8
JO - MOL DIAGN THER
JF - MOL DIAGN THER
SN - 1177-1062
IS - 1
ER -